Arcellx, Inc. is a clinical-stage biotechnology company that focuses on developing immunotherapies for patients suffering from cancer and other incurable diseases. They have formulated different product candidates, including CART-ddBCMA and ACLX-001, that are used for treating relapsed or refractory multiple myeloma, acute myeloid leukemia, and myelodysplastic syndrome, among others. The company was established in 2014 and is located in Gaithersburg, Maryland.